Gestational trophoblastic neoplasia: A 6 year retrospective study

• Main Authors: Sushruta Shrivastava, Amal Chandra Kataki, Debabrata Barmon, Pankaj Deka, Chidananda Bhuyan, Saikia J Bhargav
• Format: Article
• Language: English
• Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2014-01-01
• Series: South Asian Journal of Cancer
• Subjects: Actinomycin-D; choriocarcinoma; chemotherapy; EMACO regimen; gestational trophoblastic neoplasia; Methotrexate
• Online Access: http://journal.sajc.org/article.asp?issn=2278-330X;year=2014;volume=3;issue=1;spage=33;epage=37;aulast=Shrivastava
• ISSN: 2278-330X; 2278-4306

Aims and Objectives: To study the clinical presentations of gestational trophoblastic neoplasia and its response to chemotherapy. Materials and Methods: This is a retrospective study of 28 women of gestational trophoblastic neoplasia evaluated over a period of 6 years from January 2004 to December 2009. Patients were evaluated on the basis of their age, number of deliveries, history of abortion or molar pregnancy, and the treatment received. All patients were scored on the basis of WHO scoring system. Patients with low risk (score </=6) received single agent chemotherapy with methotrexate or actinomycin D. Patients with high risk (score >/=7) received multiple agent chemotherapy with EMACO regimen. After completion of chemotherapy patients were followed for a minimum of 2 years. The response to treatment was evaluated during follow-up by clinical examination, beta hCG levels and imaging as and when required. Results: Out of 28 women only 27 could be evaluated, because 1 patient was lost to follow-up. Out of 27 patients, 18 patients (66.67%) achieved complete remission with the first-line chemotherapy and additional 25.92% (7/27) achieved complete remission with second line chemotherapy resulting in complete remission of 92.5% (25/27). Conclusion: Gestational trophoblastic neoplasia is curable if patient is properly evaluated and scored. It shows good response to chemotherapy.